These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 782698)

  • 1. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
    Anderson T; DeVita T; Young RC
    Cancer Treat Rep; 1976 Jun; 60(6):761-7. PubMed ID: 782698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
    Williams SF; Bitran JD
    Hematol Oncol Clin North Am; 1989 Jun; 3(2):319-30. PubMed ID: 2663830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
    Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL
    Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group.
    Gams RA; Durant JR; Bartolucci AA
    Cancer Treat Rep; 1982 Apr; 66(4):899-905. PubMed ID: 7042089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group Study.
    Weick JK; Jones SE; Haut A; Fisher R; Dixon D
    Cancer Treat Rep; 1981; 65(7-8):611-4. PubMed ID: 6166373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Southeastern Cancer Study Group trials with nitrosoureas in Hodgkin's disease.
    Durant JR; Bartolucci A; Gams RA; Dorfman RF; Velez-Garcia E
    Cancer Treat Rep; 1976 Jun; 60(6):781-7. PubMed ID: 782700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 9. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
    Rege VB; Owens AH
    Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
    Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
    Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrosoureas in multiple myeloma.
    Salmon SE
    Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
    Burns LJ; Daniels KA; McGlave PB; Miller WJ; Ramsay NK; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1995 Jul; 16(1):13-8. PubMed ID: 7581112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.